Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD)

Journal of Biological Chemistry

Volumn 290, Issue 14, 2015, Pages 8711-8721

  Elmes, Matthew W ^a   Kaczocha, Martin ^a,b   Berger, William T ^a   Leung, KwanNok ^a   Ralph, Brian P ^a   Wang, Liqun ^a   Sweeney, Joseph M ^a   Miyauchi, Jeremy T ^a   Tsirka, Stella E ^a   Ojima, Iwao ^a   Deutsch, Dale G ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME ACTIVITY; HYDROPHOBICITY; NEUROLOGY;

COMPUTATIONAL ANALYSIS; FATTY ACID-BINDING PROTEINS; HYDROPHOBIC COMPOUNDS; INTRACELLULAR PROTEINS; LIGAND DISPLACEMENT; MECHANISM OF ACTION; NEUROLOGICAL DISORDERS; SITE DIRECTED MUTAGENESIS;

FATTY ACIDS;

ANANDAMIDE; CANNABIDIOL; DRONABINOL; FATTY ACID AMIDASE; FATTY ACID BINDING PROTEIN; CARRIER PROTEIN;

ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; SPECIES DIFFERENCE; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; HELA CELL LINE; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

CANNABIS; CANNABIS SATIVA; RODENTIA;

AMINO ACID SEQUENCE; ANIMALS; CANNABIDIOL; CARRIER PROTEINS; DRONABINOL; FATTY ACID-BINDING PROTEINS; HELA CELLS; HUMANS; MICE; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; RATS; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION;

EID: 84926482961     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.618447     Document Type: Article

References (73)

1. Happyana, N., Agnolet, S., Muntendam, R., Van Dam, A., Schneider, B., and Kayser, O. (2013) Analysis of cannabinoids in laser-microdissected trichomes of medicinal Cannabis sativa using LCMS and cryogenic NMR. Phytochemistry 87, 51-59
2. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R., and Pertwee, R. G. (2002) International Union of Pharmacology: XXVII. classification of cannabinoid receptors. Pharmacol. Rev. 54, 161-202
3. Pertwee, R. G. (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br. J. Pharmacol. 153, 199-215
4. Izzo, A. A., Borrelli, F., Capasso, R., Di Marzo, V., and Mechoulam, R. (2009) Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci. 30, 515-527
5. Mechoulam, R., and Parker, L. A. (2013) The endocannabinoid system and the brain. Annu. Rev. Psychol. 64, 21-47
6. Zanelati, T. V., Biojone, C., Moreira, F. A., Guimarães, F. S., and Joca, S. R. (2010) Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br. J. Pharmacol. 159, 122-128
7. Hayakawa, K., Mishima, K., Nozako, M., Ogata, A., Hazekawa, M., Liu, A. X., Fujioka, M., Abe, K., Hasebe, N., Egashira, N., Iwasaki, K., and Fujiwara, M. (2007) Repeated treatment with cannabidiol but not Δ9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. Neuropharmacology 52, 1079-1087
8. Gomes, F. V., Resstel, L. B., and Guimarães, F. S. (2011) The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology 213, 465-473
9. Fanali, G., Cao, Y., Ascenzi, P., Trezza, V., Rubino, T., Parolaro, D., and Fasano, M. (2011) Binding of Δ9-tetrahydrocannabinol and diazepam to human serum albumin. IUBMB life 63, 446-451
10. Huestis, M. A. (2005) Pharmacokinetics and metabolism of the plant cannabinoids, Δ9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb. Exp. Pharmacol. 168, 657-690
11. Kaczocha, M., Glaser, S. T., and Deutsch, D. G. (2009) Identification of intracellular carriers for the endocannabinoid anandamide. Proc. Natl. Acad. Sci. U.S.A. 106, 6375-6380
12. Kaczocha, M., Vivieca, S., Sun, J., Glaser, S. T., and Deutsch, D. G. (2012) Fatty acid-binding proteins transport N-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors. J. Biol. Chem. 287, 3415-3424
13. Björklund, E., Blomqvist, A., Hedlin, J., Persson, E., and Fowler, C. J. (2014) Involvement of fatty acid amide hydrolase and fatty acid binding protein 5 in the uptake of anandamide by cell lines with different levels of fatty acid amide hydrolase expression: a pharmacological study. PloS One 9, e103479
14. Berger, W. T., Ralph, B. P., Kaczocha, M., Sun, J., Balius, T. E., Rizzo, R. C., Haj-Dahmane, S., Ojima, I., and Deutsch, D. G. (2012) Targeting fatty acid binding protein (FABP) anandamide transporters: a novel strategy for development of anti-inflammatory and anti-nociceptive drugs. PLoS One 7, e50968
15. Oddi, S., Fezza, F., Pasquariello, N., D'Agostino, A., Catanzaro, G., De Simone, C., Rapino, C., Finazzi-Agrò, A., and Maccarrone, M. (2009) Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins. Chem. Biol. 16, 624-632
16. Kaczocha, M., Rebecchi, M. J., Ralph, B. P., Teng, Y. H., Berger, W. T., Galbavy, W., Elmes, M. W., Glaser, S. T., Wang, L., Rizzo, R. C., Deutsch, D. G., and Ojima, I. (2014) Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia. PloS One 9, e94200
17. Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., and Koethe, D. (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2, e94
18. Furuhashi, M., and Hotamisligil, G. S. (2008) Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discov. 7, 489-503
19. Balius, T. E., Mukherjee, S., and Rizzo, R. C. (2011) Implementation and evaluation of a docking-rescoring method using molecular footprint comparisons. J. Comput. Chem. 32, 2273-2289
20. Balendiran, G. K., Schnutgen, F., Scapin, G., Borchers, T., Xhong, N., Lim, K., Godbout, R., Spener, F., and Sacchettini, J. C. (2000) Crystal structure and thermodynamic analysis of human brain fatty acid-binding protein. J. Biol. Chem. 275, 27045-27054
21. Hohoff, C., Börchers, T., Rüstow, B., Spener, F., and van Tilbeurgh, H. (1999) Expression, purification, and crystal structure determination of recombinant human epidermal-type fatty acid binding protein. Biochemistry 38, 12229-12239
22. Min, X., Thibault, S. T., Porter, A. C., Gustin, D. J., Carlson, T. J., Xu, H., Lindstrom, M., Xu, G., Uyeda, C., Ma, Z., Li, Y., Kayser, F., Walker, N. P., and Wang, Z. (2011) Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH). Proc. Natl. Acad. Sci. U.S.A. 108, 7379-7384
23. Ahn, K., Johnson, D. S., Mileni, M., Beidler, D., Long, J. Z., McKinney, M. K., Weerapana, E., Sadagopan, N., Liimatta, M., Smith, S. E., Lazerwith, S., Stiff, C., Kamtekar, S., Bhattacharya, K., Zhang, Y., Swaney, S., Van Becelaere, K., Stevens, R. C., and Cravatt, B. F. (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem. Biol. 16, 411-420
24. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E. (2004) UCSF Chimera: a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612
25. Mukherjee, S., Balius, T. E., and Rizzo, R. C. (2010) Docking validation resources: protein family and ligand flexibility experiments. J. Chem. Inf. Model. 50, 1986-2000
26. Iskedjian, M., Bereza, B., Gordon, A., Piwko, C., and Einarson, T. R. (2007) Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr. Med. Res. Opin. 23, 17-24
27. Huang, Y., and Rizzo, R. C. (2012) A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases. Biochemistry 51, 2390-2406
28. Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. D., Kalé, L., and Schulten, K. (2005) Scalable molecular dynamics with NAMD. J. Comput. Chem. 26, 1781-1802
29. Case, D. A., Darden, T. A., Cheatham, T. E., Simmerling, C. L., Wang, J., Duke, R. E., Luo, R., Merz, K. M., Wang, B., Pearlman, D. A., Crowley, M., Brozell, S., Tsui, V., Gohlke, H., Mongan, J., Hornak, V., Cui, G., Beroza, P., Schafmeister, C., Caldwell, J. W., Ross, W. S., and Kollman, P. A. (2004) AMBER8, University of California, San Francisco
30. Harnak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., and Simmerling, C. (2006) Comparison of multiple amber force fields and development of improved protein backbone ParaMETERS. Proteins 65, 712-725
31. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., and Klein, M. L. (1983) Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926-935
32. Balius, T. E., and Rizzo, R. C. (2009) Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry 48, 8435-8448
33. Feller, S. E., Zhang, Y., Pastor, R. W., and Brooks, B. R. (1995) Constant pressure molecular dynamics simulations: the langevin piston method. J. Chem. Phys. 103, 4613-4621
34. Ryckaert, J.-P., Ciccotti, G., and Berendsen, H. J. C. (1977) Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 23, 327-341
35. Darden, T., York, D., and Pedersen, L. (1993) Particle mesh Ewald: an N log(N) method for Ewald sums in large systems. J. Chem. Phys. 98, 10089-10092
36. Srinivasan, J., Cheatham, T. E. I., Cieplak, P., Kollman, P. A., and Case, D. A. (1998) Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices. J. Am. Chem. Soc. 120, 9401-9409
37. rd (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 33, 889-897
38. Onufriev, A., Bashford, D., and Case, D. A. (2004) Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins 55, 383-394
39. Sitkoff, D., Sharp, K. A., and Honig, B. (1994) Accurate calculation of hydration free-energies using macroscopic solvent models. J. Phys. Chem. 98, 1978-1988
40. Case, D. A., Darden, T., Cheatham, T. E. I., Simmerling, C., Wang, J., Duke, R. E., Luo, R., Walker, R. C., Zhang, W., Merz, K. M., Roberts, B. P., Hayik, S., Roitberg, A., Seabra, G., Swails, J., Gotz, A. W., Kolossvary, I., Wong, K. F., Paesani, F., Vanicek, J., Wolf, R. M., Liu, J., Wu, X., Brozell, S. R., Steinbrecher, T., Gohlke, H., Cai, Q., Ye, X., Wang, J., Hsieh, M.-J., Cui, G., Roe, D. R., Mathews, D. H., Seetin, M. G., Salomon-Ferrer, R., Sagui, C., Babin, V., Luchko, T., Gusarov, S., Kovalenko, A., and Kollman, P. A. (2012) AMBER12, University of California, San Francisco, CA
41. Ahn, S. M., Byun, K., Cho, K., Kim, J. Y., Yoo, J. S., Kim, D., Paek, S. H., Kim, S. U., Simpson, R. J., and Lee, B. (2008) Human microglial cells synthesize albumin in brain. PloS One 3, e2829
42. Day, T. A., Rakhshan, F., Deutsch, D. G., and Barker, E. L. (2001) Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol. Pharmacol. 59, 1369-1375
43. Deutsch, D. G., Glaser, S. T., Howell, J. M., Kunz, J. S., Puffenbarger, R. A., Hillard, C. J., and Abumrad, N. (2001) The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J. Biol. Chem. 276, 6967-6973
44. Kaczocha, M., Glaser, S. T., Chae, J., Brown, D. A., and Deutsch, D. G. (2010) Lipid droplets are novel sites of N-acylethanolamine inactivation by fatty acid amide hydrolase-2. J. Biol. Chem. 285, 2796-2806
45. Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., and Di Marzo, V. (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134, 845-852
46. Ligresti, A., Moriello, A. S., Starowicz, K., Matias, I., Pisanti, S., De Petrocellis, L., Laezza, C., Portella, G., Bifulco, M., and Di Marzo, V. (2006) Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther. 318, 1375-1387
47. De Petrocellis, L., Ligresti, A., Moriello, A. S., Allará, M., Bisogno, T., Petrosino, S., Stott, C. G., and Di Marzo, V. (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br. J. Pharmacol. 163, 1479-1494
48. Mileni, M., Johnson, D. S., Wang, Z., Everdeen, D. S., Liimatta, M., Pabst, B., Bhattacharya, K., Nugent, R. A., Kamtekar, S., Cravatt, B. F., Ahn, K., and Stevens, R. C. (2008) Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc. Natl. Acad. Sci. U.S.A. 105, 12820-12824
49. Bracey, M. H., Hanson, M. A., Masuda, K. R., Stevens, R. C., and Cravatt, B. F. (2002) Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 298, 1793-1796
50. Mileni, M., Garfunkle, J., DeMartino, J. K., Cravatt, B. F., Boger, D. L., and Stevens, R. C. (2009) Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by α-ketoheterocycle inhibitors revealed from cocrystal structures. J. Am. Chem. Soc. 131, 10497-10506
51. Sanson, B., Wang, T., Sun, J., Wang, L., Kaczocha, M., Ojima, I., Deutsch, D., and Li, H. (2014) Crystallographic study of FABP5 as an intracellular endocannabinoid transporter. Acta Crystallogr. D Biol. Crystallogr. 70, 290-298
52. Di Marzo, V., Melck, D., Bisogno, T., and De Petrocellis, L. (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21, 521-528
53. Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., López-Rodriguez, M. L., Casanova, E., Schütz, G., Zieglgänsberger, W., Di Marzo, V., Behl, C., and Lutz, B. (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84-88
54. Basavarajappa, B. S. (2007) Neuropharmacology of the endocannabinoid signaling system: molecular mechanisms, biological actions and synaptic plasticity. Curr. Neuropharmacol. 5, 81-97
55. Howlett, A. C., Reggio, P. H., Childers, S. R., Hampson, R. E., Ulloa, N. M., and Deutsch, D. G. (2011) Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br. J. Pharmacol. 163, 1329-1343
56. Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., and Gilula, N. B. (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-87
57. Deutsch, D. G., and Chin, S. A. (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46, 791-796
58. Costa, B., Comelli, F., Bettoni, I., Colleoni, M., and Giagnoni, G. (2008) The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARγ receptors and neurotrophic factors. Pain 139, 541-550
59. García Mdel, C., Adler-Graschinsky, E., and Celuch, S. M. (2009) Enhancement of the hypotensive effects of intrathecally injected endocannabinoids by the entourage compound palmitoylethanolamide. Eur. J. Pharmacol. 610, 75-80
60. Ben-Shabat, S., Fride, E., Sheskin, T., Tamiri, T., Rhee, M. H., Vogel, Z., Bisogno, T., De Petrocellis, L., Di Marzo, V., and Mechoulam, R. (1998) An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 353, 23-31
61. Walter, C., Ferreirós, N., Bishay, P., Geisslinger, G., Tegeder, I., and Lötsch, J. (2013) Exogenous Δ(9)-tetrahydrocannabinol influences circulating endogenous cannabinoids in humans. J. Clin. Psychopharmacol. 33, 699-705
62. Yu, S., Levi, L., Casadesus, G., Kunos, G., and Noy, N. (2014) Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor β/δ (PPARβ/δ) in the brain. J. Biol. Chem. 289, 12748-12758
63. 3H-cannabidiol: penetration and regional distribution in rat brain. Pharmacol. Biochem. Behav. 12, 217-221
64. Huestis, M. A. (2007) Human cannabinoid pharmacokinetics. Chem. Biodiversity 4, 1770-1804
65. Bergamaschi, M. M., Barnes, A., Queiroz, R. H., Hurd, Y. L., and Huestis, M. A. (2013) Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine. Anal. Bioanal. Chem. 405, 4679-4689
66. Hunt, C. A., Jones, R. T., Herning, R. I., and Bachman, J. (1981) Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. J. Pharmacokinetics Biopharmaceutics 9, 245-260
67. Nadulski, T., Pragst, F., Weinberg, G., Roser, P., Schnelle, M., Fronk, E. M., and Stadelmann, A. M. (2005) Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Δ9-tetrahydrocannabinol (THC) after oral application of THC versus standardized cannabis extract. Therap. Drug Monitoring 27, 799-810
68. McArdle, K., Mackie, P., Pertwee, R., Guy, G., Whittle, B., and Hawksworth, G. (2001) Selective inhibition of Δ(9)-tetrahydrocannabinol metabolite formation by cannabidiol in vitro. Toxicology 168, 133-134
69. Meiri, E., Jhangiani, H., Vredenburgh, J. J., Barbato, L. M., Carter, F. J., Yang, H. M., and Baranowski, V. (2007) Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr. Med. Res. Opin. 23, 533-543
70. Tomida, I., Azuara-Blanco, A., House, H., Flint, M., Pertwee, R. G., and Robson, P. J. (2006) Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J. Glaucoma 15, 349-353
71. Devinsky, O., Cilio, M. R., Cross, H., Fernandez-Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras-Aswad, D., Notcutt, W. G., Martinez-Orgado, J., Robson, P. J., Rohrback, B. G., Thiele, E., Whalley, B., and Friedman, D. (2014) Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55, 791-802
72. Langford, R. M., Mares, J., Novotna, A., Vachova, M., Novakova, I., Notcutt, W., and Ratcliffe, S. (2013) A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J. Neurol. 260, 984-997
73. Collin, C., Davies, P., Mutiboko, I. K., Ratcliffe, S., and Sativex Spasticity in MS Study Group (2007) Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol. 14, 290-296